

Atty. Dkt.  
No.

M#

Client Ref.

056291-5004

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicant: Evans et al.

Appln. No.: 09/756,291

Filing Date: January 9, 2001

Date: September 13, 2002

Page 1 of 1

Examiner: Hui, San Ming R.

Group Art Unit: 1617

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						
DR						
ER						
FR						
GR						
HR						
IR						

**FOREIGN PATENT DOCUMENTS**

Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
JR				Enclosed	No
KR					
LR					
MR					
NR					
OR					
PR					
QR					

**OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

SM	RR	Howell et al., "Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer", The Lancet, Jan. 7, 1995, pp. 29-30
SM	SR	Osborne et al., "Comparison of the Effects of a Pure Steroidal Antiestrogen With Those of Tamoxifen in a Model of Human Breast Cancer", Journal of the National Cancer, May 1995, Vol. 87, No. 10, pp. 746-750
SM	TR	Robertson et al., "A PARTIALLY-BLIND, RANDOMISED, MULTICENTRE STUDY COMPARING THE ANTI-TUMOR EFFECTS OF SINGLE DOSES (50, 125 AND 250MG) OF LONG-ACTING (LA) 'FASLODEX' (ICI 182,780 WITH TAMOXIFIN IN POSTMENOPAUSAL WOMEN WITH PRIMARY BREAST CANCER PRIOR TO SURGERY"; Abstract 28, 22nd Annual San Antonio Breast Cancer Symposium: Dec. 8-11, 1999, San Antonio, Breast Cancer Research and Treatment 1999; 57 (1; special issue); p. 31
	UR	

Examiner

Date Considered: 11/21/02

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.